Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
about
Pharmacological interventions for pain in children and adolescents with life-limiting conditionsBisphosphonate therapy for osteogenesis imperfectaBisphosphonate therapy for osteogenesis imperfectaCalcium supplementation for improving bone mineral density in childrenSclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesRecognizing and treating secondary osteoporosisThe management of osteoporosis in children.Managing the patient with osteogenesis imperfecta: a multidisciplinary approach.Bisphosphonate treatment for children with disabling conditions.The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutationsEvaluation of teriparatide treatment in adults with osteogenesis imperfecta.Current and emerging treatments for the management of osteogenesis imperfecta.Fractures in myelomeningocele.RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.Molecular, phenotypic aspects and therapeutic horizons of rare genetic bone disorders.Bisphosphonate therapy for osteogenesis imperfecta.Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatmentBisphosphonate treatment of bone diseaseChanging pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonatesSystematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritisAtypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report.Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.Ginsenoside Rg1 promotes osteogenic differentiation of rBMSCs and healing of rat tibial fractures through regulation of GR-dependent BMP-2/SMAD signaling.Management pitfalls of fractured neck of femur in osteogenesis imperfectaTreatment of osteogenesis imperfecta: who, why, what?Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formationThe effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition.Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.Optimization of Bone Health in Children before and after Renal Transplantation: Current Perspectives and Future Directions.Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study.Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfectaNew perspectives on osteogenesis imperfectaMeasures of self-care independence for children with osteochondrodysplasia: a clinimetric review.Osteogenesis imperfecta: diagnosis and treatment.Femoral neck fractures in osteogenesis imperfecta treated with bisphosphonates.Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
P2860
Q24187283-93276D00-9276-47A1-BC57-40AF8EB2F62AQ24194821-A7726178-FEEA-4689-AB95-4F3D0695AA39Q24240782-4AF14669-849D-422D-A399-272CEA35DE0CQ24246305-C121F015-5958-4428-9C28-FE7550FF52D6Q26744599-B9853468-7268-4741-82BD-6609645616BDQ28270738-EE76DFA3-78A5-4721-9E31-511219381FDBQ30251490-B4B129DF-57F2-40A6-A185-99E4AC993C77Q33554034-F2D80CCC-76F7-4E67-8FE4-AA15C6D0E35FQ33680621-E8A50C22-644F-4476-B04E-C2EE3BA95F64Q33781943-120A852C-474E-4FAD-9B5A-7A1DF745AB54Q33847609-E569A018-32EC-4C23-B04D-F3A816918F20Q34039676-6964BB96-D0EB-4757-A703-E9B4827ABA44Q34133308-5A65C1D5-3BE4-416C-B5FA-3842B4B7CA94Q34166648-C7BC868E-2FAD-433C-94CF-1BDAB7F831C0Q34234347-8B65EE05-0B2D-4C93-9C80-EAAFA1E43EA7Q34502398-CBE39F1B-B65F-427A-9A73-6C0222B9EFA5Q34543060-0A904F3E-7B00-4850-863D-9B29278B1F1BQ34678492-9036CC10-9E23-4A02-A9BB-67A84B5DC096Q34759279-AE725FC7-4710-44C9-B7F0-39135BD25FEBQ35283631-78AB6CD3-1A30-48C9-8B4A-77A05A760F31Q35828143-C0E12924-573C-484C-ADB6-428825F12401Q36153306-EC9317E0-194A-45EF-8FA3-B97D46AC5371Q36368632-6C25B6BF-5686-4E3D-A6D5-ADD1E7AC9699Q36472781-B4B2CCF7-2A28-43F0-BF5C-849C6F217CE6Q36864808-6EF7CA74-346C-428B-8B9F-62EB23CF4657Q36902343-41892542-6227-4548-8958-4F15F749810CQ37050007-9BEFFB74-9696-4F2E-B033-F49D3BD71292Q37158425-9D1E8B9E-D65A-4258-BDCD-F7B3B0CBEF3CQ37166804-2E3709D8-5991-46E4-83C9-04743CD9C27CQ37167038-C95E5C94-7B06-4464-BC02-29A980EBC2C0Q37522199-47742B4A-F922-4B15-9097-5C7C70B4F9CEQ37579579-BD6C6107-9C9F-41C0-89ED-2EA453572297Q37598894-FA79FD2E-90E0-4D0A-9C96-CD69A4E93CD7Q37717395-229DA1D0-7437-4F68-8066-D8C543894915Q37722288-80711187-F9A9-40A3-ADE7-582AE105BDD6Q37889113-DDF15096-90F0-4F18-A1D0-5EC804C6D1FBQ37897576-34E9CEF8-6A17-425F-AAA5-0850ADCDFA5AQ38223208-869635EA-7D39-4FB9-A0A7-1464EE6DB9A1Q38615041-4D639F7A-847D-4077-9CB5-D4CB3864B9C3Q38617388-8035A747-5334-4E3E-B658-A23C573E6CE7
P2860
Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Skeletal effects and functiona ...... ised placebo-controlled study.
@ast
Skeletal effects and functiona ...... ised placebo-controlled study.
@en
type
label
Skeletal effects and functiona ...... ised placebo-controlled study.
@ast
Skeletal effects and functiona ...... ised placebo-controlled study.
@en
prefLabel
Skeletal effects and functiona ...... ised placebo-controlled study.
@ast
Skeletal effects and functiona ...... ised placebo-controlled study.
@en
P2093
P1433
P1476
Skeletal effects and functiona ...... ised placebo-controlled study.
@en
P2093
Ab Verbout
Alice van Dongen
Cuno Uiterwaal
Dave Schweitzer
Hans Pruijs
Maarten Jansen
Ralph Sakkers
Raoul Engelbert
P304
P356
10.1016/S0140-6736(04)16101-1
P407
P577
2004-05-01T00:00:00Z